Published in J Clin Microbiol on February 01, 1998
Multicenter evaluation of the AMPLICOR and automated COBAS AMPLICOR CT/NG tests for detection of Chlamydia trachomatis. J Clin Microbiol (2000) 3.44
Discrepant analysis: how can we test a test? J Clin Microbiol (2000) 2.99
Development and evaluation of a real-time PCR assay targeting the type III secretion system of Burkholderia pseudomallei. J Clin Microbiol (2006) 2.94
Detection of Chlamydia trachomatis and Neisseria gonorrhoeae by enzyme immunoassay, culture, and three nucleic acid amplification tests. J Clin Microbiol (2001) 2.38
Comparison of three nucleic acid amplification tests for detection of Chlamydia trachomatis in urine specimens. J Clin Microbiol (2004) 2.26
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Diagnosis and assessment of trachoma. Clin Microbiol Rev (2004) 1.96
Head-to-head multicenter comparison of DNA probe and nucleic acid amplification tests for Chlamydia trachomatis infection in women performed with an improved reference standard. J Clin Microbiol (2002) 1.85
Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis. Clin Vaccine Immunol (2007) 1.70
Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn (2006) 1.70
Use of multiple nucleic acid amplification tests to define the infected-patient "gold standard" in clinical trials of new diagnostic tests for Chlamydia trachomatis infections. J Clin Microbiol (2004) 1.57
Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program. J Clin Microbiol (2009) 1.47
Confirmation by 16S rRNA PCR of the COBAS AMPLICOR CT/NG test for diagnosis of Neisseria gonorrhoeae infection in a low-prevalence population. J Clin Microbiol (2002) 1.46
Use of the Roche LightCycler instrument in a real-time PCR for Trichomonas vaginalis in urine samples from females and males. J Clin Microbiol (2003) 1.39
Nucleic acid amplification tests for diagnosis of Neisseria gonorrhoeae and Chlamydia trachomatis rectal infections. J Clin Microbiol (2010) 1.33
Performance of the gen-probe transcription-mediated [corrected] amplification research assay compared to that of a multitarget real-time PCR for Mycoplasma genitalium detection. J Clin Microbiol (2006) 1.28
Comparison of multiplex PCR assay with culture for detection of genital mycoplasmas. J Clin Microbiol (2004) 1.27
Evaluation of the Biostar Chlamydia OIA assay with specimens from women attending a sexually transmitted disease clinic. J Clin Microbiol (1998) 1.12
Estimating diagnostic accuracy of multiple binary tests with an imperfect reference standard. Stat Med (2009) 0.97
Discrepant analysis is an inappropriate and unscientific method. J Clin Microbiol (2000) 0.96
Utility of real-time PCR for diagnosis of Legionnaires' disease in routine clinical practice. J Clin Microbiol (2007) 0.95
Detection of Streptococcus pyogenes by use of Illumigene group A Streptococcus assay. J Clin Microbiol (2013) 0.94
Relative accuracy of nucleic acid amplification tests and culture in detecting Chlamydia in asymptomatic men. J Clin Microbiol (2001) 0.90
Performance of a commercial polymerase chain reaction test for endocervical Chlamydia trachomatis infection in a university hospital population. Infect Dis Obstet Gynecol (1998) 0.81
Evaluation of a modified sanitary napkin as a sample self-collection device for the detection of genital chlamydial infection in women. J Clin Microbiol (2001) 0.75
Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine. Lancet (1995) 7.46
Detection of Chlamydia trachomatis in endocervical specimens by polymerase chain reaction. J Clin Microbiol (1992) 6.33
Diagnosis of Chlamydia trachomatis infections in men and women by testing first-void urine by ligase chain reaction. J Clin Microbiol (1994) 5.61
The discrepancy in discrepant analysis. Lancet (1996) 5.16
Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix. J Clin Microbiol (1994) 5.15
Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev (1997) 4.37
Diagnosis of Chlamydia trachomatis urethral infection in symptomatic and asymptomatic men by testing first-void urine in a ligase chain reaction assay. J Infect Dis (1994) 3.93
Diagnosis of Chlamydia trachomatis endocervical infections by a commercial polymerase chain reaction assay. J Clin Microbiol (1993) 3.82
Detection of Chlamydia trachomatis in urine specimens from women by ligase chain reaction. J Clin Microbiol (1995) 3.58
Amplification of Chlamydia trachomatis DNA by ligase chain reaction. J Clin Microbiol (1993) 3.53
Bias in the evaluation of DNA-amplification tests for detecting Chlamydia trachomatis. Stat Med (1997) 3.22
Random effects models in latent class analysis for evaluating accuracy of diagnostic tests. Biometrics (1996) 2.78
Rapid diagnosis of sexually transmitted diseases--speed has a price. Diagn Microbiol Infect Dis (1986) 2.69
Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review. J Clin Epidemiol (1988) 2.64
Use of the polymerase chain reaction for the detection of Chlamydia trachomatis from endocervical and urine specimens in an asymptomatic low-prevalence population of women. Diagn Microbiol Infect Dis (1994) 2.09
Role of confirmatory PCRs in determining performance of Chlamydia Amplicor PCR with endocervical specimens from women with a low prevalence of infection. J Clin Microbiol (1994) 1.94
Underdiagnosis of Chlamydia trachomatis infection. Diagnostic limitations in patients with low-level infection. Sex Transm Dis (1992) 1.57
Effect of patient characteristics on performance of an enzyme immunoassay for detecting cervical Chlamydia trachomatis infection. J Clin Microbiol (1990) 1.48
Latent variable modeling of diagnostic accuracy. Biometrics (1997) 1.34
Blood pyruvate in vitamin B(1) deficiency. Biochem J (1935) 8.97
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Environment and Food Intake in Man. Science (1947) 5.68
Laboratory testing for Neisseria gonorrhoeae by recently introduced nonculture tests: a performance review with clinical and public health considerations. Clin Infect Dis (1998) 3.69
National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results. N Engl J Med (1976) 3.63
Roles of yeast DNA polymerases delta and zeta and of Rev1 in the bypass of abasic sites. Genes Dev (2001) 3.59
Efficient and accurate replication in the presence of 7,8-dihydro-8-oxoguanine by DNA polymerase eta. Nat Genet (2000) 3.39
Chlamydia trachomatis infections in the United States. What are they costing us? JAMA (1987) 3.32
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Selection bias from requiring patients to give consent to examine data for health services research. Arch Fam Med (2001) 3.08
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Health care episodes: definition, measurement and use. Med Care Rev (1985) 3.03
Accuracy of thymine-thymine dimer bypass by Saccharomyces cerevisiae DNA polymerase eta. Proc Natl Acad Sci U S A (2000) 2.89
Structure of the catalytic core of S. cerevisiae DNA polymerase eta: implications for translesion DNA synthesis. Mol Cell (2001) 2.88
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Physical and functional interactions of human DNA polymerase eta with PCNA. Mol Cell Biol (2001) 2.84
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Fidelity and processivity of Saccharomyces cerevisiae DNA polymerase eta. J Biol Chem (1999) 2.54
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Linkage analysis of malignancy-associated sarcoidosis. Chest (1995) 2.34
A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther (1988) 2.32
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Requirement of DNA polymerase eta for error-free bypass of UV-induced CC and TC photoproducts. Mol Cell Biol (2001) 2.28
Targeting of human DNA polymerase iota to the replication machinery via interaction with PCNA. Proc Natl Acad Sci U S A (2001) 2.26
Tamoxifen in the management of pseudoangiomatous stromal hyperplasia. Breast J (2002) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Requirement of yeast SGS1 and SRS2 genes for replication and transcription. Science (1999) 2.01
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
ATP Sulfurylase Activity in the Soybean [Glycine max (L.) Merr.]. Plant Physiol (1968) 1.83
National gonorrhea therapy monitoring study: treatment results. N Engl J Med (1976) 1.82
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Race and the prevalence of syphilis seroreactivity in the United States population: a national sero-epidemiologic study. Am J Public Health (1989) 1.77
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Bridging the gap: a family of novel DNA polymerases that replicate faulty DNA. Proc Natl Acad Sci U S A (1999) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest (1992) 1.75
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
BLOOD LACTATE RESPONSE DURING MODERATE EXERCISE IN NEUROCIRCULATORY ASTHENIA, ANXIETY NEUROSIS, OR EFFORT SYNDROME. J Clin Invest (1947) 1.70
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther (1988) 1.68
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Composition and dynamics of plasma in Saturn's magnetosphere. Science (2005) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Cassini finds an oxygen-carbon dioxide atmosphere at Saturn's icy moon Rhea. Science (2010) 1.58
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
The dust halo of Saturn's largest icy moon, Rhea. Science (2008) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos (1985) 1.49
Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (1994) 1.49
An Evaluation of a Teat Dip with Dodecyl Benzene Sulfonic Acid in Preventing Bovine Mammary Gland Infection from Experimental Exposure to Streptococcus agalactiae and Staphylococcus aureus. Can Vet J (1982) 1.48
Recent changes in the incidence of duodenal and gastric ulcer. Am J Epidemiol (1980) 1.48
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings. Sex Transm Dis (1998) 1.46
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend (1994) 1.45
Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J (1999) 1.44
Progress in systemic sclerosis: a 10-year perspective. Rheumatology (Oxford) (2009) 1.44
Antiviral activity of some beta-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses. J Med Chem (1977) 1.44
Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol (2000) 1.42
Treatment of opioid-dependent pregnant women with buprenorphine. Addiction (2000) 1.41
Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis (1991) 1.41
Antireticulin antibody in systemic sclerosis. Ann Rheum Dis (1990) 1.40
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med (1972) 1.40
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest (2001) 1.39
Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res (1971) 1.38
Five patients who developed systemic sclerosis shortly after episodes of physical trauma. J Rheumatol (1996) 1.38
Anti-PL 4 in patients with systemic lupus erythematosus with severe renal and haematological disease. QJM (1997) 1.38
Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther (2008) 1.38
Enzyme immunoassay to determine exposure to Chlamydia pneumoniae (strain TWAR). J Clin Microbiol (1989) 1.37
Flagellar hydrodynamics. A comparison between resistive-force theory and slender-body theory. Biophys J (1979) 1.35
Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) (2001) 1.35
Use of prostate-specific antigen for prostate cancer screening in primary care practice. Arch Fam Med (1995) 1.34
IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest (1996) 1.34
Erythromycin in the treatment of acute bronchitis in a community practice. J Fam Pract (1986) 1.33
Addition of monoclonal antibodies specific for Rickettsia akari to the rickettsial diagnostic panel. J Clin Microbiol (1988) 1.32
European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis (2003) 1.32